| 4.47 0 (0%) | 08-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.3 |
1-year : | 5.4 |
| Resists | First : | 4.53 |
Second : | 4.62 |
| Pivot price | 4.47 | |||
| Supports | First : | 4.4 | Second : | 3.66 |
| MAs | MA(5) : | 4.48  |
MA(20) : | 4.48 |
| MA(100) : | 4.35 |
MA(250) : | 10.18 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 31.3 |
| RSI | RSI(14): 49.3 | |||
| 52-week | High : | 25.45 | Low : | 3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CRGX ] has closed above bottom band by 42.5%. Bollinger Bands are 85.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.48 - 4.5 | 4.5 - 4.52 |
| Low: | 4.41 - 4.44 | 4.44 - 4.46 |
| Close: | 4.43 - 4.47 | 4.47 - 4.51 |
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Tue, 19 Aug 2025
Cargo Therapeutics acquired by Concentra Biosciences, delisted from Nasdaq - Investing.com
Tue, 08 Jul 2025
Concentra to acquire CARGO Therapeutics for $4.38 per share - Investing.com
Tue, 08 Jul 2025
CARGO Therapeutics to be acquired by Concentra Biosciences in $4.379/share cash deal plus CVR; stock rises 8% - Seeking Alpha
Tue, 08 Jul 2025
CARGO Therapeutics Enters into Agreement to Be Acquired by - GlobeNewswire
Tue, 08 Jul 2025
Major Biotech Deal: Concentra Acquires CARGO Therapeutics at Premium Price Plus Additional Value Rights - Stock Titan
Thu, 09 Nov 2023
CARGO Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 99.2 (%) |
| Shares Short | 3,040 (K) |
| Shares Short P.Month | 3,090 (K) |
| EPS | -4.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -65.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -190 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -0.97 |
| PEG Ratio | 0 |
| Price to Book value | 0.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|